Anixa Biosciences (ANIX) Competitors $3.38 -0.06 (-1.74%) Closing price 04:00 PM EasternExtended Trading$3.38 0.00 (-0.15%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ANIX vs. PRTA, ALMS, ZVRA, ETHZ, EOLS, INBX, FULC, SLDB, ATXS, and KMDAShould you be buying Anixa Biosciences stock or one of its competitors? The main competitors of Anixa Biosciences include Prothena (PRTA), Alumis (ALMS), Zevra Therapeutics (ZVRA), Flag Ship Acquisition (ETHZ), Evolus (EOLS), Inhibrx Biosciences (INBX), Fulcrum Therapeutics (FULC), Solid Biosciences (SLDB), Astria Therapeutics (ATXS), and Kamada (KMDA). These companies are all part of the "pharmaceutical products" industry. Anixa Biosciences vs. Its Competitors Prothena Alumis Zevra Therapeutics Flag Ship Acquisition Evolus Inhibrx Biosciences Fulcrum Therapeutics Solid Biosciences Astria Therapeutics Kamada Anixa Biosciences (NASDAQ:ANIX) and Prothena (NASDAQ:PRTA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, valuation, profitability, media sentiment, analyst recommendations, earnings, institutional ownership and dividends. Which has more volatility & risk, ANIX or PRTA? Anixa Biosciences has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500. Comparatively, Prothena has a beta of -0.04, meaning that its stock price is 104% less volatile than the S&P 500. Is ANIX or PRTA more profitable? Anixa Biosciences has a net margin of 0.00% compared to Prothena's net margin of -2,929.30%. Prothena's return on equity of -62.17% beat Anixa Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Anixa BiosciencesN/A -67.45% -59.18% Prothena -2,929.30%-62.17%-54.43% Does the media favor ANIX or PRTA? In the previous week, Anixa Biosciences had 4 more articles in the media than Prothena. MarketBeat recorded 6 mentions for Anixa Biosciences and 2 mentions for Prothena. Prothena's average media sentiment score of 1.28 beat Anixa Biosciences' score of 0.20 indicating that Prothena is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anixa Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Prothena 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher valuation & earnings, ANIX or PRTA? Anixa Biosciences has higher earnings, but lower revenue than Prothena. Anixa Biosciences is trading at a lower price-to-earnings ratio than Prothena, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnixa BiosciencesN/AN/A-$12.55M-$0.35-9.57Prothena$135.16M3.79-$122.31M-$5.64-1.69 Do institutionals & insiders hold more shares of ANIX or PRTA? 29.1% of Anixa Biosciences shares are owned by institutional investors. Comparatively, 97.1% of Prothena shares are owned by institutional investors. 25.3% of Anixa Biosciences shares are owned by company insiders. Comparatively, 9.2% of Prothena shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Do analysts prefer ANIX or PRTA? Anixa Biosciences currently has a consensus target price of $9.00, suggesting a potential upside of 168.66%. Prothena has a consensus target price of $19.75, suggesting a potential upside of 107.28%. Given Anixa Biosciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe Anixa Biosciences is more favorable than Prothena.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anixa Biosciences 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Prothena 1 Sell rating(s) 4 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.33 SummaryAnixa Biosciences beats Prothena on 8 of the 15 factors compared between the two stocks. Get Anixa Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ANIX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ANIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANIX vs. The Competition Export to ExcelMetricAnixa BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$110.27M$3.07B$5.65B$10.30BDividend YieldN/A2.36%5.68%4.61%P/E Ratio-9.5720.8575.8526.09Price / SalesN/A397.84514.78169.46Price / CashN/A45.9137.5661.52Price / Book7.139.6212.886.30Net Income-$12.55M-$52.73M$3.29B$271.03M7 Day Performance-0.59%0.77%-0.25%-0.14%1 Month Performance11.67%6.48%3.88%6.44%1 Year Performance6.35%19.04%68.42%28.85% Anixa Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANIXAnixa Biosciences3.0101 of 5 stars$3.38-1.7%$9.00+166.3%+1.8%$111.26MN/A-9.665Analyst ForecastPRTAProthena3.1639 of 5 stars$8.29+2.7%$19.75+138.2%-57.7%$434.41M$135.16M-1.47130Positive NewsALMSAlumis3.5098 of 5 stars$4.15-0.5%$20.17+385.9%-63.8%$433.95MN/A0.00N/AZVRAZevra Therapeutics2.7759 of 5 stars$7.95+3.7%$23.71+198.3%+8.2%$430.56M$23.61M-37.8620News CoverageOptions VolumeGap UpETHZFlag Ship AcquisitionN/A$2.40-5.1%N/AN/A$416.01MN/A-0.167Options VolumeGap DownEOLSEvolus3.9426 of 5 stars$6.31+0.3%$21.25+236.8%-61.4%$406.87M$266.27M-6.44170Positive NewsINBXInhibrx Biosciences1.1404 of 5 stars$27.12-1.7%N/A+91.6%$399.80M$200K-2.56166Positive NewsFULCFulcrum Therapeutics1.9446 of 5 stars$7.45+0.8%$9.60+28.9%+157.0%$399.74M$80M-6.11100Positive NewsSLDBSolid Biosciences2.8554 of 5 stars$5.17+1.0%$15.00+190.1%-18.8%$398.69M$8.09M-1.85100ATXSAstria Therapeutics2.949 of 5 stars$7.51+6.5%$30.20+302.1%-41.8%$397.87MN/A-3.7430KMDAKamada4.5354 of 5 stars$6.99+1.2%$13.00+86.0%+28.5%$397.36M$160.95M20.56360Positive News Related Companies and Tools Related Companies Prothena Alternatives Alumis Alternatives Zevra Therapeutics Alternatives Flag Ship Acquisition Alternatives Evolus Alternatives Inhibrx Biosciences Alternatives Fulcrum Therapeutics Alternatives Solid Biosciences Alternatives Astria Therapeutics Alternatives Kamada Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ANIX) was last updated on 9/25/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Anixa Biosciences Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Anixa Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ANIX Stock Alerts